NASDAQ:BRKR - Bruker Stock Price, Price Target & More

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker announced a quarterly dividend on Tuesday, May 15th. Shareholders of record on Monday, June 4th will be given a dividend of $0.04 per share on Friday, June 22nd. This represents a $0.16 annualized dividend and a yield of 0.54%. The ex-dividend date is Friday, June 1st. View Bruker's Dividend History.

Bruker declared that its Board of Directors has authorized a share repurchase program on Sunday, June 4th 2017, which allows the company to buyback $225,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company's management believes its stock is undervalued.

Bruker Co. (NASDAQ:BRKR) issued its quarterly earnings results on Thursday, May, 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.22 by $0.02. The medical research company had revenue of $431.70 million for the quarter, compared to analysts' expectations of $419.25 million. Bruker had a net margin of 4.63% and a return on equity of 27.04%. The business's revenue for the quarter was up 12.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share. View Bruker's Earnings History.

Bruker is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Bruker.

9 equities research analysts have issued 1 year target prices for Bruker's stock. Their predictions range from $24.00 to $42.00. On average, they expect Bruker's share price to reach $32.8889 in the next year. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Ratings for Bruker.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Bruker include Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT) and HTG Molecular Diagnostics (HTGM).

News headlines about BRKR stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bruker earned a news impact score of 0.14 on Accern's scale. They also assigned media stories about the medical research company an impact score of 46.56 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Bruker's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.12%), Cambiar Investors LLC (0.10%), Thompson Rubinstein Investment Management Inc. OR (0.09%), Fisher Asset Management LLC (0.09%), Clinton Group Inc. (0.03%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Bruker stock include Frank H Laukien, Ingen Chris Van, Mark Munch, Richard A Packer and Richard Kniss. View Institutional Ownership Trends for Bruker.

BRKR stock was sold by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, Fisher Asset Management LLC and Scout Investments Inc.. View Insider Buying and Selling for Bruker.

BRKR stock was bought by a variety of institutional investors in the last quarter, including Clinton Group Inc., Fox Run Management L.L.C., Thompson Rubinstein Investment Management Inc. OR and State of Alaska Department of Revenue. Company insiders that have bought Bruker stock in the last two years include Frank H Laukien and Richard A Packer. View Insider Buying and Selling for Bruker.

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BRKR stock can currently be purchased for approximately $29.72.

Bruker has a market capitalization of $4.51 billion and generates $1.77 billion in revenue each year. The medical research company earns $78.60 million in net income (profit) each year or $1.21 on an earnings per share basis. Bruker employs 6,200 workers across the globe.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at 978-663-3660 or via email at [email protected]